Nurix Therapeutics, Inc. announced the closing of its previously announced global collaboration agreement with Roche to co-develop and co-commercialize bexobrutideg, following expiration of the waiting period under the… read more.
Pfizer Japan Inc. and Eisai Co., Ltd. announced that the companies will commence the co-promotion of the oral calcitonin gene-related peptide (CGRP) receptor antagonist Nurtec OD Tablet 75mg… read more.
Organon announced the completion of a global licensing agreement with Sebela Pharmaceuticals, granting Organon exclusive rights to MIUDELLA, a hormone-free, copper intrauterine device (IUD). Please see our prior… read more.
Shionogi & Co., Ltd. announced that they have completed the transfer of all rights for Radicava (edaravone), including intellectual property rights and sales rights, in major countries and… read more.
Pelthos Therapeutics Inc. announced it has acquired Xeglyze (abametapir) from Hatchtech Pty Ltd., an Australian biotech company, for $1.8 million. Xeglyze is a pediculicide indicated for the topical… read more.
Organon announced that it has entered into an agreement with Laborie Medical Technologies Corp., a leading diagnostic and therapeutic medical technology company, for them to acquire the JADA… read more.
Pelthos Therapeutics Inc. announced it has acquired the U.S. marketing rights to Xepi (ozenoxacin) Cream, 1%, from Biofrontera Inc. and Ferrer Internacional S.A. (the Xepi is a non-fluorinated… read more.
Boston Scientific Corporation announced the close of its acquisition of Relievant Medsystems Inc., a company that offers the only FDA -cleared Intracept Intraosseous Nerve Ablation System, a therapy… read more.
BioDelivery Sciences International, Inc. a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, announced that it has completed the acquisition of U.S. and Canadian rights… read more.
Following the news of the acquisition of Vectura by Philip Morris International (PMI), we would like to clarify GSK’s position regarding Ellipta inhalers and their association with Vectura.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
